Kala Bio poised to ship first commercial AI product in about 14 days

Kala Bio (KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry through its Researgency.ai platform, deploying purpose-built AI agents that handle the repetitive, high-stakes jobs that slow drug companies down, faster, cheaper, and with fewer errors than humans. With the full rebrand of Researgency.ai now complete, the platform is live and ready for enterprise clients. Kala’s scientists, working alongside Younet’s AI engineering team, are building the company’s first custom AI agent right now, with delivery expected in approximately 14 days. This is not a rebranding announcement – this is a go-to-market readiness signal.